With a wealth of scientific discovery, Canada is primed to be a global leader in life sciences.

To realize this potential, adMare uses its scientific and commercial expertise, specialized R&D infrastructure, and investment capital to build investable companies, robust ecosystems and industry-ready talent – and re-invests its returns back into the Canadian industry to ensure it is sustained for the long-term.

In 2022, adMare BioInnovations gave its support to Domain Therapeutics and invested in the group to support its advancement to the clinic stage.